On August 26, 2026, the FDA approved daraxonrasib (Rasonque®) for metastatic pancreatic adenocarcinoma after ≥1 prior systemic therapy—the first broadly applicable targeted therapy for this disease. A Clinical Cancer Bulletin commentary highlights phase III RASolute 302: in RAS G12-mutant patients, median OS was 13.2 vs. 6.6 months with chemotherapy (HR 0.40), ORR 31.6%, and better safety, surpassing first-line FOLFIRINOX (11.1 months). This first-in-class RAS(ON) multi-selective inhibitor targets GTP-bound KRAS/NRAS/HRAS across G12/G13/Q61, covering >90% of patients and breaking RAS’s “undruggable” barrier. Resistance and earlier/combination use remain challenges.

Today, the American Association for Cancer Research (AACR) released the 16th edition of its annual Cancer Progress Report. This comprehensive report provides current data on cancer incidence, mortality, and survivorship. It also outlines how basic, translational, and clinical cancer research and cancer-related population science—largely supported by federal investments in the National Institutes of Health (NIH), the National Cancer Institute (NCI), the U.S. Food and Drug Administration (FDA), and the Centers for Disease Control and Prevention (CDC)—are improving health and saving lives.

Structured exercise may help people with cancer live longer and have more time free of disease, finds a synthesis of the available evidence, published online in the British Journal of Sports Medicine.

The multicenter phase 1/2 trial will be conducted across the U.S. over the next five years and will be the first prospective human study to test a treatment specifically aimed at the condition. 

The University of Texas MD Anderson Cancer Center and Springer Nature will co-host a conference to explore the latest research on cancer therapeutics, highlighting advances in the development of next-generation treatment modalities and the technologies enabling them. “Next Generation Cancer Therapeutics” is scheduled for Oct. 6-8, 2026, on the UT MD Anderson campus. 

U.S. News & World Report has recognized Dana-Farber/Boston Children’s Cancer and Blood Disorders Center as the #1 pediatric cancer program in the nation in its 2026-2027 Best Children’s Hospitals report. Dana-Farber/Boston Children’s has been recognized as one of the top three pediatric cancer centers in the country each year since the ranking’s inception in 2007, earning more #1 rankings than any other program.